Serial Microbiota Analysis after Fecal Microbiota Transplantation in a Child with Down's Syndrome

Yvette H. Van Beurden, Lisethe Meijer, Clementien L. Vermont, Andries E. Budding, Chris J. J. Mulder, Tim G. De Meij

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Fecal microbiota transplantation (FMT) is a very effective treatment for recurrent Clostridium difficile infection (CDI) in adults. However, there is a paucity of data on FMT in children and associated microbiome changes in this particular group. We describe a child with Down's syndrome and intracranial malignancy, who received FMT for recurrent CDI. Detailed microbiota analysis before and after FMT, and pre- and post-recurrence, linked to microbial communities in the donor feces showed that the patient developed a unique microbiota profile after FMT which was very stable over time despite CDI recurrence and subsequent fidaxomicin therapy. Bacteroidetes were stably acquired from donor feces, while Firmicutes, Actinobacteria, Fusobacteria, Verrucomicrobia, and Proteobacteria were unique to the patient. The diversity of microbiota of the patient increased from a Shannon diversity index of 2.08 pre-FMT to 3.12 post-FMT. Our findings underscore that patients with Down's syndrome may well tolerate and benefit from FMT even in a severely immunocompromised state.
Original languageEnglish
Pages (from-to)136-139
JournalJOURNAL OF PEDIATRIC INFECTIOUS DISEASES
Volume14
Issue number3
DOIs
Publication statusPublished - 2019

Cite this

Beurden, Yvette H. Van ; Meijer, Lisethe ; Vermont, Clementien L. ; Budding, Andries E. ; Mulder, Chris J. J. ; Meij, Tim G. De. / Serial Microbiota Analysis after Fecal Microbiota Transplantation in a Child with Down's Syndrome. In: JOURNAL OF PEDIATRIC INFECTIOUS DISEASES. 2019 ; Vol. 14, No. 3. pp. 136-139.
@article{36bd1ef407644e9aa193bff7a7e1b94e,
title = "Serial Microbiota Analysis after Fecal Microbiota Transplantation in a Child with Down's Syndrome",
abstract = "Fecal microbiota transplantation (FMT) is a very effective treatment for recurrent Clostridium difficile infection (CDI) in adults. However, there is a paucity of data on FMT in children and associated microbiome changes in this particular group. We describe a child with Down's syndrome and intracranial malignancy, who received FMT for recurrent CDI. Detailed microbiota analysis before and after FMT, and pre- and post-recurrence, linked to microbial communities in the donor feces showed that the patient developed a unique microbiota profile after FMT which was very stable over time despite CDI recurrence and subsequent fidaxomicin therapy. Bacteroidetes were stably acquired from donor feces, while Firmicutes, Actinobacteria, Fusobacteria, Verrucomicrobia, and Proteobacteria were unique to the patient. The diversity of microbiota of the patient increased from a Shannon diversity index of 2.08 pre-FMT to 3.12 post-FMT. Our findings underscore that patients with Down's syndrome may well tolerate and benefit from FMT even in a severely immunocompromised state.",
author = "Beurden, {Yvette H. Van} and Lisethe Meijer and Vermont, {Clementien L.} and Budding, {Andries E.} and Mulder, {Chris J. J.} and Meij, {Tim G. De}",
year = "2019",
doi = "10.1055/s-0037-1606330",
language = "English",
volume = "14",
pages = "136--139",
journal = "JOURNAL OF PEDIATRIC INFECTIOUS DISEASES",
issn = "1305-7707",
publisher = "IOS Press",
number = "3",

}

Serial Microbiota Analysis after Fecal Microbiota Transplantation in a Child with Down's Syndrome. / Beurden, Yvette H. Van; Meijer, Lisethe; Vermont, Clementien L.; Budding, Andries E.; Mulder, Chris J. J.; Meij, Tim G. De.

In: JOURNAL OF PEDIATRIC INFECTIOUS DISEASES, Vol. 14, No. 3, 2019, p. 136-139.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Serial Microbiota Analysis after Fecal Microbiota Transplantation in a Child with Down's Syndrome

AU - Beurden, Yvette H. Van

AU - Meijer, Lisethe

AU - Vermont, Clementien L.

AU - Budding, Andries E.

AU - Mulder, Chris J. J.

AU - Meij, Tim G. De

PY - 2019

Y1 - 2019

N2 - Fecal microbiota transplantation (FMT) is a very effective treatment for recurrent Clostridium difficile infection (CDI) in adults. However, there is a paucity of data on FMT in children and associated microbiome changes in this particular group. We describe a child with Down's syndrome and intracranial malignancy, who received FMT for recurrent CDI. Detailed microbiota analysis before and after FMT, and pre- and post-recurrence, linked to microbial communities in the donor feces showed that the patient developed a unique microbiota profile after FMT which was very stable over time despite CDI recurrence and subsequent fidaxomicin therapy. Bacteroidetes were stably acquired from donor feces, while Firmicutes, Actinobacteria, Fusobacteria, Verrucomicrobia, and Proteobacteria were unique to the patient. The diversity of microbiota of the patient increased from a Shannon diversity index of 2.08 pre-FMT to 3.12 post-FMT. Our findings underscore that patients with Down's syndrome may well tolerate and benefit from FMT even in a severely immunocompromised state.

AB - Fecal microbiota transplantation (FMT) is a very effective treatment for recurrent Clostridium difficile infection (CDI) in adults. However, there is a paucity of data on FMT in children and associated microbiome changes in this particular group. We describe a child with Down's syndrome and intracranial malignancy, who received FMT for recurrent CDI. Detailed microbiota analysis before and after FMT, and pre- and post-recurrence, linked to microbial communities in the donor feces showed that the patient developed a unique microbiota profile after FMT which was very stable over time despite CDI recurrence and subsequent fidaxomicin therapy. Bacteroidetes were stably acquired from donor feces, while Firmicutes, Actinobacteria, Fusobacteria, Verrucomicrobia, and Proteobacteria were unique to the patient. The diversity of microbiota of the patient increased from a Shannon diversity index of 2.08 pre-FMT to 3.12 post-FMT. Our findings underscore that patients with Down's syndrome may well tolerate and benefit from FMT even in a severely immunocompromised state.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063229665&origin=inward

U2 - 10.1055/s-0037-1606330

DO - 10.1055/s-0037-1606330

M3 - Article

VL - 14

SP - 136

EP - 139

JO - JOURNAL OF PEDIATRIC INFECTIOUS DISEASES

JF - JOURNAL OF PEDIATRIC INFECTIOUS DISEASES

SN - 1305-7707

IS - 3

ER -